C

Cencora

Distributes medicines and supports patient care

Field & Infusion Nurse - Registered Practical Nurse/Licensed Practical Nurse

Part-TimeUpdated on 10/22/2026
No salary listed
Junior
Bachelor's
Hanover, ON, Canada+1 moreMore locations: Owen Sound, ON, Canada
In PersonTravel is required within the designated and surrounding IBUs, clinics, and homecare appointments within a set geographic boundary.
Medical, Clinical & VeterinaryNursing & Frontline Patient Care

About the job

Requirements
  • A bachelor's degree in nursing, clinical practice, health sciences, public health, healthcare administration, or a related field, or equivalent experience, is required.
  • A professional nursing license or registration in the applicable jurisdiction is required.
  • At least 2 years of experience as a Registered Practical Nurse or Licensed Practical Nurse is required.
  • A current registration with the provincial licensing body and a CPR certificate are required.
  • Experience in an acute-care inpatient or outpatient setting, or a homecare setting, is required.
  • Knowledge of using a cell phone to make and confirm appointments or assignments and using fax machines is required.
  • The candidate must be able to work autonomously with little supervision as part of a larger team.
  • The candidate must be able to travel to clinics and homecare appointments within a set geographic boundary.
  • The candidate must hold and maintain a valid, non-expired, unrestricted driver's license and insurance coverage.
  • The successful candidate may have daily contact with unilingual English-speaking customers, patients, or cross-functional peers.
Responsibilities
  • Administer medications, including intramuscular, subcutaneous, and intravenous medications as applicable, in home or specialty-clinic settings.
  • Support and monitor administration of intravenous infusion treatments in clinic or homecare settings.
  • Monitor post-injection and infusion treatments, and chart and report activities as directed by program protocols and professional nursing documentation standards.
  • Provide patient education based on program protocols, individually or in groups.
  • Report adverse events, serious adverse events, and product complaints in accordance with Innomar training and policies and procedures.
  • Maintain reliable availability under the agreed employment agreement to meet the needs of the IBU and the Nursing and clinics key performance indicators.
  • Coordinate daily with patients, case managers, physicians, scheduling, and other departments to meet timelines for appointments, treatments, and communication.
  • Perform administrative duties such as monthly clinic audits and supply ordering.
  • Participate regularly in team web-based meetings and training sessions with the Business Area Manager, RNE, and Nurse Champion to maintain and enhance professional practice standards.
  • Participate in specialized client-related training as required.
  • Consult with physicians, pharmaceutical and biotechnology clients regarding education and implementation of product-specific programs.
  • Travel within the designated IBU and surrounding IBUs to meet operational needs.
  • Follow nursing and clinic standard operating procedures and work instructions.
  • Follow health and safety standards under the provincial Health and Safety Act.
  • Complete ongoing and annual education training within specified timeframes.
  • Adhere to professional nursing standards prescribed by professional associations, regulatory bodies, and company policies and procedures.
  • Perform related duties and tasks as required by Innomar.
Desired Qualifications
  • Certification in clinical services, care coordination, patient safety, or equivalent is preferred.
  • Certification in case management, clinical documentation improvement, healthcare quality, or equivalent is preferred.
  • Experience with intravenous therapy is an asset.
  • Advanced Cardiovascular Life Support, Pediatric Advanced Life Support, Multiple Sclerosis, and CVAA certifications, as well as central venous line or port experience, are considered assets.
  • Flexibility to provide services for pre-scheduled and occasional last-minute patient appointment requests is desired.
  • Effective organizational skills and attention to detail are desired.
  • The ability to communicate effectively orally and in writing is desired.
  • Strong written and verbal communication skills are desired.
  • The ability to work in both team and independent settings is desired.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.